Journal of Clinical and Translational Hepatology

Journal Information
ISSN / EISSN : 22250719 / 23108819
Current Publisher: Xia & He Publishing Inc. (10.14218)
Total articles ≅ 296
Current Coverage
PUBMED
PMC
ESCI
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Hisao Hayashi, Kazumasa Watanabe, Ayano Inui, Ayako Kato, Yasuaki Tatsumi, Akihiko Okumura, Tomoo Fujisawa, Koichi Kato
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-4; doi:10.14218/jcth.2019.00042

Daud H. Akhtar, Umair Iqbal, Luis Miguel Vazquez-Montesino, Brittany B. Dennis, Aijaz Ahmed
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-9; doi:10.14218/jcth.2019.00028

Cyriac Abby Philips, Sasidharan Rajesh, Tom George, Rizwan Ahamed, Sandeep Kumbar, Philip Augustine
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-12; doi:10.14218/jcth.2019.00043

Vinay B. Pawar, Ravindra G. Surude, Nikhil Sonthalia, Vinay Zanwar, Samit Jain, Qais Contractor, Pravin M. Rathi
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-9; doi:10.14218/jcth.2017.00037

Anil Seetharam
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-8; doi:10.14218/jcth.2019.00032

Victoria Jaeger, Sharon DeMorrow, Matthew McMillin
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-10; doi:10.14218/jcth.2019.00025

Leon D. Averbukh, George Y. Wu
Journal of Clinical and Translational Hepatology pp 1-6; doi:10.14218/jcth.2019.00023

Cyriac Abby Philips, Philip Augustine, Rizwan Ahamed, Sasidharan Rajesh, Tom George, Gopakumar C. Valiathan, Solomon K. John
Journal of Clinical and Translational Hepatology pp 1-13; doi:10.14218/jcth.2019.00034

Shousheng Liu, Yongning Xin
Journal of Clinical and Translational Hepatology, Volume 7, pp 195-196; doi:10.14218/JCTH.2019.00047

Xiaoyuan Xu, Bo Feng, Yujuan Guan, Sujun Zheng, Jifang Sheng, Xingxiang Yang, Yuanji Ma, Yan Huang, Yi Kang, Xiaofeng Wen, et al.
Journal of Clinical and Translational Hepatology, Volume 7, pp 213-220; doi:10.14218/JCTH.2019.00033

Abstract:Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is the first phase 2/3 study conducted in Mainland China confirming the efficacy and safety of RDV + ritonavir-boosted danoprevir + ribavirin for 12 weeks in treatment-naïve noncirrhotic patients with genotype 1 infection in a large population. Methods: In this multicenter, randomized, double-blinded, placebo-controlled phase 2/3 trial (NCT03362814), we enrolled 424 treatment-naïve, noncirrhotic adult HCV genotype 1 patients. All patients were randomized at 3:1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day (body weight <75/≥75 kg) (n = 318) or placebo (n = 106) for 12 weeks. The primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment, and the safety was evaluated and compared between treatment and placebo groups. Results: The overall rate of sustained virological response at 12 weeks after treatment is 99% (306/309, 95%, CI: 97%-100%) under per protocol set analysis. All patients harboring baseline NS5A resistance-associated species in the treatment group (76/76, per protocol set) achieved sustained virological response at 12 weeks after treatment. No treatment-related serious adverse events were reported. Laboratory abnormalities showed mild or moderate severity (grade 1 and grade 2) in liver function tests. Conclusions: In treatment-naïve, noncirrhotic HCV Chinese patients infected with HCV genotype 1, all-oral regimen of RDV + ritonavir-boosted danoprevir + ribavirin for 12 weeks was highly efficacious, safe, and well tolerated.